Remuneration Principles
Contents

1. The Board of Directors ................................................................. 3
2. Executive Management ............................................................... 4
3. Overview .................................................................................... 7
Principles for remuneration of board members and executives in Novo Nordisk A/S (Remuneration Principles) 1,2

The Remuneration Principles are designed to attract, retain and motivate the members of the Board of Directors and of Executive Management. Remuneration has been designed to align the interests of the executives with those of the shareholders.

1. The Board of Directors

1.1 Process
The Board of Directors reviews board fees annually based on recommendations from the Remuneration Committee. When preparing its recommendation, the Remuneration Committee will evaluate board fees against relevant benchmarks of Danish and other Nordic companies as well as European pharmaceutical companies similar to Novo Nordisk in size, complexity and market capitalisation. The remuneration of the board members for the past year and the level for the current year are approved by the Annual General Meeting as a separate agenda item.

1.2 Size
Each board member shall receive a fixed fee per year. Board members receive a fixed amount (the base fee) while the Chairmanship receives a multiple thereof: the chairman receives 3 times the base fee and the vice chairman receives 2 times the base fee.

Service on the Audit Committee entitles board members to an additional fee: the Audit Committee chairman receives 1.00 times the base fee and the other Audit Committee members receive 0.5 times the base fee.

Service on the Nomination Committee, Remuneration Committee and Research and Development Committee entitles board members to an additional fee: the Committee chairman receives 0.5 times the base fee and the other Committee members receive 0.25 times the base fee.

Individual board members may take on specific ad hoc tasks outside their normal duties assigned by the Board. In each such case the Board shall determine a fixed fee (e.g. per diem) for the work carried out related to those tasks. The fixed fee will be disclosed in the Annual Report.

1.3 Social security taxes
Novo Nordisk pays in addition to the fixed fee such contribution to social security taxes within the EU imposed by foreign authorities in relation to the fixed fee.

1.4 Travel allowance
All board members are paid a fixed travel allowance when travelling to board meetings or committee related meetings. No travel allowance is paid to board members when no travel is required to attend board meetings or committee related meetings. The travel allowance will be disclosed in the Annual Report.

1.5 Expenses
Expenses such as travel and accommodation in relation to board meetings as well as relevant education are reimbursed.

1.6 Incentive programmes
Board members are not offered stock options, warrants or participation in other incentive schemes.

1 In Section 4 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen referred to as “remuneration policy”.
2 These Principles include general guidelines for incentive-based remuneration pursuant to Section 139 of the Danish Companies Act.
2. **Executive Management**

Executive Management includes all the executives registered as executives with the Danish Business Authority.

2.1 **Process**
Executive remuneration is proposed by the Remuneration Committee and subsequently approved by the Board.

2.2 **Size and composition**
Executive remuneration is evaluated annually against relevant benchmarks of Danish and other Nordic companies as well as European pharmaceutical companies similar to Novo Nordisk in terms of size, complexity and market capitalisation. To ensure comparability, executive positions are evaluated in accordance with an international position evaluation system which among other parameters includes and reflects the development of the company size measured in terms of company revenue and number of employees.

The remuneration package consists of a fixed base salary, a cash-based incentive, a long-term share-based incentive, a pension contribution and other benefits.

For executives on an international assignment at the request of the company, the remuneration package is generally based on an equalized host country net salary during the length of the assignment.

The fixed base salary is chosen to attract and retain executives with professional and personal competences required to drive the company’s performance.

The Short-term incentive programme (STIP) is designed to incentivise the individual executive for individual performance within his/her functional area and to ensure short-term achievements in line with company needs.

The Long-term incentive programme (LTIP) is designed to promote the collective performance of Executive Management and to align the interests of executives and shareholders. It further ensures a balance between short-term achievements and long-term thinking.

Pension contributions are made to provide an opportunity for executives to build up an income for retirement. Other benefits are added to ensure that overall remuneration is competitive and aligned with local practice.

2.3 **Size of the components**
The fixed base salary accounts for approximately 15% to 35% of the total value of the remuneration package. The interval states the span between “maximum performance” and “on-target-performance”.

In addition to the fixed base salary, the executives may be eligible for variable incentive-based remuneration consisting of 1) a STIP, and 2) a LTIP. The STIP may result in a maximum payout per year equal to 12 months’ fixed base salary plus pension contribution. The LTIP may result in a maximum share allocation per year equal to 24 months’ fixed base salary plus pension contribution. Consequently, the aggregate maximum amount that may be granted as incentive for a given year is equal to 36 months’ fixed base salary plus pension contribution.

This split between fixed and variable remuneration is intended to result in a reasonable part of the salary being linked to performance, while at the same time promoting sound business decisions to achieve the company’s vision. Further, the balance between the components is assessed broadly to be in line with market practice for benchmarked companies.

2.4 **Incentive programmes**

1. **Short-term incentive programme (STIP)**
The STIP consists of a cash-based incentive which is linked to the achievement of a number of predefined functional and individual business targets for each member of Executive Management. The STIP for each executive
cannot exceed an amount equal to 12 months’ fixed base salary plus pension contribution per year. The Board of Directors determines at the beginning of each year the maximum STIP for each executive for the given year. The calculation of the STIP – if any – for a year is typically based on the salary in December. The targets for the chief executive officer are fixed by the chairman of the Board of Directors while the targets for the executive vice presidents are fixed by the chief executive officer. The chairman of the Board evaluates the degree of target achievement for each member of Executive Management, and cash-based incentives – if any – for a particular financial year are paid at the beginning of the subsequent financial year.

STIP is subject to recovery or ‘claw-back’ by Novo Nordisk, provided the remuneration was paid on the basis of data which proved to be manifestly misstated. Claw-back in relation to the STIP is possible up to 12 months after the actual payment of the cash-based incentive.

2. **Long-term incentive programme (LTIP)**

Each year in January the Board of Directors decides whether or not to establish an LTIP for that calendar year.

The LTIP is based on an annual calculation of economic value creation as compared to the budgeted performance for the year and on sales compared to the budgeted target for the year.

Aligned with Novo Nordisk’s long-term financial targets, the calculation of economic value creation is based on reported operating profit after tax reduced by a weighted average cost of capital (WACC)-based return requirement on average invested capital.

For members of Executive Management the LTIP operates with a yearly maximum share allocation per executive equal to 18 months’ fixed base salary plus pension contribution for the chief executive officer and 13.5 months’ fixed base salary plus pension contribution for the executive vice presidents. The Board of Directors determines at the beginning of each year the maximum allocation per executive for the given year. Further, the Board of Directors identifies a number of significant research and development projects and key sustainability projects and the allocation per executive may, subject to the Board of Directors’ assessment, be reduced in case of lower-than-planned performance on these research and development projects and key sustainability projects. Targets for non-financial performance related to sustainability and research and development projects may include achievement of certain milestones within set dates. Finally, the Board of Directors determines the expected average annual sales growth which shall be used as basis when finally calculating the size of the allocation at the end of the three-year vesting period given that the allocation can be reduced or increased by up to 30% depending on the average sales growth in the three-year vesting period.

Once the allocation per executive has been approved by the Board of Directors, the total cash amount is converted into Novo Nordisk A/S B shares at market price. The market price is calculated as the average trading price for Novo Nordisk A/S B shares on Nasdaq Copenhagen in the open trading window following the release of financial results for the year prior to the relevant performance year; ie in the open trading window immediately following the Board of Directors’ approval of the programme.

The shares are allocated to the executives according to their base salary as per 1 April in the performance year.

The shares allocated per executive for a given year will be locked up for three years before they are transferred to the individual executive. If an executive resigns during the vesting period, his or her allocated shares will be removed.

At the end of the vesting period the allocation of shares will be reduced or increased by up to 30% depending on whether the actual average annual sales growth in the three-year vesting period is lower or higher compared to the expected average annual sales growth. The allocation cannot exceed 24 months’ fixed base salary plus pension contribution for the chief executive officer and 18 months’ fixed base salary plus pension contribution for the executive vice presidents.
In the vesting period the market value of the allocated shares per executive will change dependent upon the development in the Novo Nordisk B share price, aligning the interests of the executives with those of shareholders.

No dividends are paid on allocated shares in the vesting period and the allocated shares are administered as part of Novo Nordisk’s holding of treasury shares.

Novo Nordisk continuously covers its obligations under the LTIP through its holding of treasury shares.

LTIP is subject to recovery or ‘claw-back’ by Novo Nordisk, provided the remuneration was paid on the basis of data which proved to be manifestly misstated. Claw-back in relation to the LTIP is possible up to 12 months after the release of the shares to the executives (ie four years after allocation).

2.5 Pension
The pension contribution is up to 25% of the fixed base salary including bonus.

2.6 Other benefits
Executives receive non-monetary benefits such as company cars, phones etc. Executives on international assignments may receive relocation benefits. Such benefits are approved by the Board by delegation of powers to the Remuneration Committee. The Remuneration Committee informs the Board of the process and outcome. In addition, executives may participate in customary employee benefit programmes, eg employee share purchase programmes.

2.7 Termination of employment
Novo Nordisk may terminate the employment of an executive by giving 12 months’ notice. Executives may terminate their employment by giving Novo Nordisk six months’ notice.

2.8 Severance payment
In the event of termination – whether by Novo Nordisk or by the individual – due to a merger, acquisition or takeover of Novo Nordisk, executives are, in addition to the notice period, entitled to a severance payment of 24 months’ fixed base salary plus pension contribution. In case of termination by Novo Nordisk for other reasons, the severance payment is three months’ fixed base salary plus pension contribution per year of employment as an executive and taking into account previous employment history; in no event, however, less than 12 or more than 24 months’ fixed base salary plus pension contribution.

With regard to severance payment, the employment contracts entered into before 2008 exceed the 24-month limit described above. The severance payment to individual executives under the contracts entered into before 2008 will, however, not exceed 36 months’ fixed base salary plus pension contributions.

The severance payment may be reduced if the executive has or takes up new employment after the expiry of the notice period. A reduction has among other things to take into consideration the size of severance payment and the remuneration related to the new employment. Severance payment under contracts entered into before 2017 with members of the Management Board may, however, not be reduced. The Management Board consists of all members of Executive Management and senior vice presidents.

2.9 Sign-on arrangement
The Board of Directors may when recruiting new executives who are not employed by Novo Nordisk at the time of employment grant a sign-on arrangement in the form of cash payment or share incentive programme.

2.10 Shareholding requirements for Executive Management
To further align the interests of the shareholders and Executive Management the chief executive officer should hold Novo Nordisk A/S B shares corresponding to 2 times the annual gross salary and the executive vice presidents
should hold shares corresponding to 1 time the annual gross salary. The Board of Directors may grant exemption to this requirement, e.g. in connection with a promotion to chief executive officer or executive vice president.

3. Overview

The below table provides an overview of the remuneration for members of the Board of Directors and Executive Management.

<table>
<thead>
<tr>
<th></th>
<th>Board of Directors</th>
<th>Executive Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed fee/base salary</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Fee for committee work</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Fee for ad hoc tasks</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>STIP (Short-term incentive programme)</td>
<td>No</td>
<td>Up to 12 months’ fixed base salary plus pension contribution per year</td>
</tr>
<tr>
<td>LTIP (Long-term incentive programme)</td>
<td>No</td>
<td>Up to 18 months’ fixed base salary plus pension contribution per year for the chief executive officer and 13.5 months’ fixed base salary plus pension contribution per year for the executive vice presidents with the possibility to reduce or increase the number of shares allocated by 30% depending on the average sales growth in the vesting period.</td>
</tr>
<tr>
<td>Pension</td>
<td>No</td>
<td>Up to 25% of fixed base salary and STIP</td>
</tr>
<tr>
<td>Travel allowance</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Other benefits</td>
<td>No</td>
<td>As approved by the Board by delegation of powers to the Remuneration Committee</td>
</tr>
<tr>
<td>Severance payment</td>
<td>No</td>
<td>Based on tenure of employment, 12–24 months’ fixed base salary plus pension contribution. However, for employment contracts entered into before 2008 such payment would be 12–36 months’ fixed base salary plus pension contribution.</td>
</tr>
</tbody>
</table>

Adopted by the Board of Directors on 31 January 2019 and approved by the Annual General Meeting on 21 March 2019.